In the September 25th article, "Health Concerns over Popular Contraceptives" published in "The New York Times" Natasha Singer speaks about two pharmaceutical drugs that are on high demand not because of the effectiveness of the drug, but more so because of the marketing placed around the two drugs. Yaz, and Yasmin are both forms of contraception that are heavily circulating as great forms of contraception; especially for women over age 35. However, Yaz in particular the "sister drug" to Yasmin is the top selling birth control pill in the U.S. This pill contains less estrogen than Yasmine and is advertised as "a quality of life treatment that will to combat acne and severe premenstrual depression.
Despite advertisements and tremendous sales worldwide for Yaz, some researchers, health advocates, and lawyers are concerned about the drug. They say that it puts women at a higher risk for blood clots, strokes and many other health problems. In addition to that The Food & Drug Administration earlier this year asked "Bayer"; the health care company producing these contraceptives to correct misleading advertisements.
Despite the ongoing research and studies surrounding the pharmaceutical, the company stood behind the safety of the drug and claimed to have taken heed to the F.D.A's questions, concerns and requests. However, industry analysts say that the Yaz product family may be tarnished due to the recent and ongoing defamation of the product.
I believe that there are always health concerns surrounding contraceptives, and in most situations that does tarnish the product name and company, but that doesn't mean that people should not voice their concern on what can become a very big health problem in the future for people, and health care. Pharmaceutical companies continuously produce misleading advertisements and marketing to sell a product, so for that reason they should be prepared to take on the consequences for doing such; even if that means losing money or gaining a bad reputation.
Full article available at
No comments:
Post a Comment